Morphine is protective against doxorubicin-induced cardiotoxicity in rat

Toxicology

Volumn 243, Issue 1-2, 2008, Pages 96-104

  Kelishomi, Roohollah Babaei ^a   Ejtemaeemehr, Shahram ^a   Tavangar, Seyed Mohammad ^b   Rahimian, Reza ^a   Mobarakeh, Jalal Izadi ^c,d   Dehpour, Ahmad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Cardiotoxicity; Doxorubicin; ECG; Morphine

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; MORPHINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; HEART LEFT VENTRICLE CONTRACTILITY; HEART PROTECTION; HEART WEIGHT; HISTOPATHOLOGY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTONIC AGENTS; DOXORUBICIN; ELECTROCARDIOGRAPHY; HEART DISEASES; MALE; MORPHINE; MYOCARDIAL CONTRACTION; MYOCARDIUM; PAPILLARY MUSCLES; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR FUNCTION, LEFT;

ANIMALIA; RATTUS;

EID: 37049011405     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2007.09.026     Document Type: Article

References (53)

1. Aitchison K.A., Baxter G.F., Awan M.M., Smith R.M., Yellon D.M., and Opie L.H. Opposing effects on infarction of delta and kappa opioid receptor activation in the isolated rat heart: implication for ischemic preconditioning. Basic Res. Cardiol. 95 (2000) 1-10
2. Arai M., Tomaru K., Takizawa T., Sekiguchi K., Yokoyama T., Suzuki T., et al. Sarcoplasmic reticulum gene are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbit. J. Mol. Cell Cardiol. 30 (1998) 243-254
3. 2+ATP-ase gene transcription. Circ. Res. 86 (2000) 8-14
4. Billingham M.E., Mason J.W., Bristow M.R., and Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep. 62 (1978) 865-872
5. Boucek R.J., Dodd D.A., Atkinson J.B., Oquist N., and Olson R.D. Contractile failure in chronic doxorubicin-induced cardiomiopathy. J. Mol. Cell Cardiol. 29 (1997) 2631-2640
6. Boucek R.J., Miracle A., Anderson M., Engelman E., Atkinson J., and Dodd D.A. Persistent effects of doxorubicin on cardiac gene expression. J. Mol. Cell Cardiol. 31 (1999) 1435-1446
7. 5-enkephalin). J. Thorac. Cardiovasc. Surg. 107 (1994) 964-967
8. Chien G.L., and Van Winkle D.M. Naloxone blockade of myocardial ischemic preconditioning is stereoselective. J. Mol. Cell Cardiol. 28 (1996) 1895-1900
9. Danesi R., Tacca M.D., and Soldan G. Measurement of the S[alpha]-T segment at the most reliable electrocardiogram parameter for the assessment of adriamycin-induced cardiotoxicity in the rat. J. Pharm. Methods 16 (1986) 251-259
10. Demant E.J., and Jensen P.K. Destruction of phospholipids and respiratory-chain activity in pig-heart submitochondrial particles induced by an Adriamycin-iron complex. Eur. J. Biochem. 132 (1983) 551-556
11. + channels: possible mechanism of cardioprotection. Circ. Res. 81 (1997) 1072-1082
12. Gross R.A., Moises H.C., Uhler M.D., and Macdonald R.L. Dynorphin A and cAMP-dependent protein kinase independently regulate neuronal calcium currents. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 7025-7029
13. Gross G.J., and Auchampach J.A. Blockade of the ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ. Res. 70 (1992) 223-233
14. Herman E.H., and Ferrans V.J. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab. Invest. 49 (1983) 69-77
15. Herman E.H., Ferrans V., Young R.S.K., and Hamlin R.L. Effects of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res. 48 (1988) 6918-6925
16. Herman E.H., Zhang J., Chadwick D.P., and Ferrans V. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother. Pharmacol. 45 (2000) 329-334
17. Hoekman K., Van der Vijgh W.J.F., and Vermorken J.B. Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer. Drugs 57 (1999) 133-156
18. Hortobagyi G.N. Anthracyclines in the treatment of cancer. An over review. Drugs 54 Suppl. 4 (1997) 1-7
19. Ito H., Miller S.C., Billingham M.E., Akimoto H., Torti S.M., Wade R., et al. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 4275-4279
20. Jaenke R.S. An anthracycline antibiotic-induced cardiomiopathy in rabbits. Lab. Invest. 30 (1974) 292-304
21. Jensen R.A., Acton E.M., and Peters J.H. Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential and structural effects. J. Cardiovasc. Pharmacol. 6 (1984) 186-200
22. Jensen R.A. Doxorubicin cardiotoxicity: contractile changes after long term treatment in the rat. J. Pharmacol. Exp. Ther. 236 (1986) 197-203
23. Jeyaseelan R., Poizet C., Hung-Yi W., and Kedes L. Molecular mechanism of doxorubicin-induced cardiomyopathy. J. Biol. Chem. 272 (1997) 5826-5832
24. Ji L.L., and Mitchel E.W. Effects of adriamycin on heart mitochondrial function in rested and exercised rats. Biochem. Pharmacol. 47 (1994) 877-885
25. Larsen R.L., Jakacki R.I., Vetter V.I., Meadows A.T., Silber J.H., and Barber G. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am. J. Cardiol. 70 (1992) 73-77
26. Liu G.S., Thornton J., Van Winkle D.M., Stanley A.W.H., Olsson R.A., and Downey J.M. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84 (1991) 350-356
27. Maslov L.N., Krylatov A.V., and Lishmanov Y.B. On the involvement of endogenous μ and δ opiate receptor agonists in the anti arrhythmic effect of adaptation. Bull. Exp. Biol. Med. 121 (1996) 20-21
28. Mayfield K.P., and D'Alecy L.G. Role of endogenous opioid peptides in the acute adaptation to hypoxia. Brain Res. 582 (1992) 226-231
29. Mayfield K.P., and D'Alecy L.G. Delta-1 opioid receptor dependence of acute hypoxic adaptation. J. Pharmacol. Exp. Ther. 268 (1994) 74-77
30. Mayfield K.P., and D'Alecy L.G. Delta-1 opioid agonist acutely increases hypoxic tolerance. J. Pharmacol. Exp. Ther. 268 (1994) 683-688
31. Meerson F.Z., Ustinova E.E., and Orlova E.H. Prevention and elimination of heart arrhythmias by adaptation to intermittent high altitude hypoxia. Clin. Cardiol. 10 (1987) 783-789
32. Murry C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986) 1124-1136
33. North R.A., Williams J.T., Surprenant A., and Christie M.J. μ- and δ-Receptors belong to a family of receptors that are coupled to potassium channels. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 5487-5491
34. Nousiainen T., Vanninen E., Ranrala A., Jantunen E., and Hartikainen J. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J. Intern. Med. 245 (1999) 359-364
35. Olson R.D., and Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4 (1990) 3076-3086
36. Powis G., and Phil D. Toxicity of free radical forming anticancer agents. In: Powis G., Phil D., and Hacker P.M. (Eds). The Toxicity of Anticancer Drugs (1991), Pergamon Press, New York 106-151
37. Rossi F., Filipelli W., Russo S., Filippelli A., and Berrino L. Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances. Pharmacol. Toxicol. 75 (1994) 99-107
38. Santos D.L., Moreno A.J.M., Leino R.L., Froberg M.K., and Wallace K.B. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol. Appl. Pharmacol. 185 (2002) 218-227
39. Schultz J.J., Rose E., Yao Z., and Gross G.J. Evidence for involvement of opioid receptors in ischemic preconditioning in rat heart. Am. J. Physiol. 268 (1995) H2157-H2161
40. Schultz J.J., Rlsu A.K., and Gross G.J. Ischemic preconditioning and morphine-induced cardioprotection involve the delta-opioid receptor in the intact rat heart. J. Mol. Cell Cardiol. 29 (1997) 2187-2195
41. Schultz J.J., Hsu A.K., Barbieri J.T., Li P.-L., and Gross G.J. Pertussis toxin abolishes the cardioprotective effect of ischemic preconditioning in the intact rat heart. Am. J. Physiol. 275 (1998) H495-H500
42. 1 but not μ or κ opioid receptors. Circulation 97 (1998) 1282-1289
43. 2+ in rat ventricular myocytes. Life Sci. 59 (1996) 2181-2186
44. Solem L.E., Henry T.R., and Wallace K. Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicol. Appl. Pharmacol. 129 (1994) 214-222
45. Tsuchida A., Miura T., Tanno M., Nozawa Y., Kita H., and Shimamoto K. Time window for the contribution of the δ opioid receptor to cardioprotection by ischemic preconditioning in the rat heart. Cardiovasc. Drugs Ther. 12 (1998) 365-373
46. van Acker S.A., Kramer K., Voest E.E., Grimbergen J.A., Zhang J., van der Vijgh W.J., et al. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors. Cancer Chemother. Pharmacol. 38 (1996) 95-101
47. 2+ release from an intracellular pool in myocytes and neurons. Circ. Res. 70 (1992) 66-81
48. Villani F., Galimberti M., Monti E., Cova D., Lanza E., Rozza-Dionigi A., et al. Effects of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat. Toxicol. Appl. Pharmacol. 102 (1990) 292-299
49. Wang G.Y., Wu S., Pei J.M., Yu X.C., and Wong T.k. K but not δ opioid receptors mediate effects of ischemic preconditioning on both infarct and arrhythmias in rats. Am. J. Physiol. 280 (2001) H384-H391
50. Yao Z., and Gross G.J. Role of nitric oxide, muscarinic receptors, and the ATP-sensitive potassium channel in mediating the effects of acetylcholine to mimic preconditioning in dogs. Circ. Res. 73 (1993) 1193-1201
51. Yoshikawa T., Handa S., Suzumi M., and Nagami K. Abnormalities in sympathoneuronal regulation are localized to failing myocardium in rabbit heart. J. Am. Coll. Cardiol. 24 (1994) 210-215
52. Ytrehus K., Liu Y., and Downey J.M. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am. J. Physiol. 266 (1994) H1145-H1152
53. Zhou S., Starkov A., Froberg M.K., Leino R.L., and Wallace K.B. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 61 (2001) 771-777